NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.

Cover of Molecular Imaging and Contrast Agent Database (MICAD)

Molecular Imaging and Contrast Agent Database (MICAD) [Internet].

Show details

99mTc(CO)3-Anti-carcinoembryonic antigen (CEA) humanized CEA5 graft nanobody

99mTc-Humanized CEA5 graft
, PhD
National for Biotechnology Information, NLM, NIH, Bethesda, MD
Corresponding author.

Created: ; Last Update: July 26, 2012.

Chemical name:99mTc(CO)3-Anti-carcinoembryonic antigen antigen (CEA) humanized CEA5 graft nanobody
Abbreviated name:99mTc-Humanized CEA5 graft
Synonym:
Agent category:Antibody fragment, humanized nanobody
Target:Carcinoembryonic antigen (CEA)
Target category:Receptor
Method of detection:Single-photon emission computed tomography (SPECT), gamma planar imaging
Source of signal:99mTc
Activation:No
Studies:
  • Checkbox In vitro
  • Checkbox Rodents
Click on protein, nucleotide (RefSeq), and gene for more information about CEA.

Background

[PubMed]

Carcinoembryonic antigen (CEA) was first identified from extracts of human colon adenocarcinoma (1) and fetal gut (2). CEA is a β-glycoprotein, and its predominant expression on the cell surface is increased in a variety of carcinomas and in certain inflammatory conditions, such as inflammatory bowel disease (3, 4). CEA has a molecular weight of ~180 kDa, and it can be shed and detected in serum (5). CEA expression is observed in patients with various carcinomas of the colon, lung, thyroid, uterus, ovary, pancreas, and medullary thyroid. Radiolabeled monoclonal antibodies (mAbs) have been developed for both the diagnosis and treatment of tumors (6, 7). However, the pharmacokinetics of intact radiolabeled mAbs, with high liver uptake and slow blood elimination, are generally not ideal for imaging (8, 9). Smaller antibody fragments, such as scFv, Fab, or F(ab')2, have better imaging pharmacokinetics because they are rapidly excreted by the kidneys. Nanobodies are the smallest intact antigen-binding fragments (15 kDa) isolated from heavy-chain camelid antibodies with efficient and specific tumor targeting (10-12). Anti-CEA nanobody CEA5 (NbCEA5, also known as cAb-CEA5) exhibits high binding affinity to CEA (Kd, 0.34 nM) (13). In order to minimize immunogenicity of nanobodies in humans, the antigen-binding loops of NbCEA5 were genetically grafted onto the framework of a humanized nanobody scaffold (h-NBBcII10FGLA) to form humanized CEA5 graft nanobody (14). The three nanobodies (NbCEA5, humanized nanobody scaffold, and humanized CEA5 graft) were radiolabeled with 99mTc using tricarbonyl chemistry for noninvasive in vivo single-photon emission computed tomography (SPECT) imaging of CEA expression in tumors in mice.

Synthesis

[PubMed]

NbCEA5, humanized nanobody scaffold, and humanized CEA5 graft were produced as hexahistidine-tagged proteins in Escherichia coli (14). A solution of [99mTc(H2O)3(CO)3]+ and nanobodies was incubated for 90 min at 52°C. 99mTc-Labeled nanobodies were isolated with column chromatography, with a radiochemical purity of >99%. The specific activities, radiochemical yields, and stability of the 99mTc-labeled nanobodies were not reported.

In Vitro Studies: Testing in Cells and Tissues

[PubMed]

Flow cytometry analysis showed that NbCEA5 and humanized CEA5 graft bound efficiently to CEA-expressing CHO and human colon adenocarcinoma LS174T cells but not to CEA-negative CHO cells (14). Humanized nanobody scaffold exhibited no binding to either CHO cell types. Binding experiments with the use of a Biacore sensor chip immobilized with CEA protein showed that the Kd values of NbCEA5, humanized nanobody scaffold, and humanized CEA5 graft were 0.34 nM, >10 µM, and 9.88 nM, respectively. 99mTc-NbCEA5 and 99mTc-humanized CEA5 graft exhibited efficient binding to both purified CEA protein and CEA-expressing CHO cells, whereas 99mTc-humanized nanobody scaffold exhibited little binding.

Animal Studies

Rodents

[PubMed]

Vaneycken et al. (14) performed SPECT imaging analysis in nude mice (n = 6) bearing LS174T tumors at 1 h after injection of 45–155 MBq (1.2–4.2 mCi, 0.17 nmol) 99mTc-NbCEA5, 99mTc- humanized CEA5 graft, or 99mTc-humanized nanobody scaffold. Intense radioactivity levels were observed in the kidneys (>87% ID/cm3) and urinary bladder for all 99mTc-nanobodies, which were cleared equally quickly from the blood. Accumulation levels in the liver, lung, and muscle were low (<3.1% ID/cm3). Radioactivity accumulation levels in the tumors for 99mTc-NbCEA5, 99mTc-humanized nanobody scaffold, and 99mTc- humanized CEA5 graft were 7.09 ± 1.36%, 0.21 ± 0.05%, and 6.15 ± 2.33% ID/cm3. The tumor accumulation of 99mTc- humanized CEA5 graft was not significantly different from that of 99mTc-NbCEA5 (P = 0.40). The imaging studies were not confirmed with ex vivo biodistribution studies, and no blocking studies were performed.

Other Non-Primate Mammals

[PubMed]

No publication is currently available.

Non-Human Primates

[PubMed]

No publication is currently available.

Human Studies

[PubMed]

No publication is currently available.

References

1.
Gold P., Freedman S.O. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. The Journal of Experimental Medicine. 1964;121:439–462. [PMC free article: PMC2137957] [PubMed: 14270243]
2.
Krupey J., Gold P., Freedman S.O. Purification and characterization of carcinoembryonic antigens of the human digestive system. Nature. 1967;215(5096):67–8. [PubMed: 6053407]
3.
Kowalsky, R.J., and S.W. Falen, Radiopharmaceuticals in nuclear pharmacy and nuclear medicine2004, American Pharmacists Association: Washington, D.C. p. 733-752.
4.
Wahl R.L., Philpott G., Parker C.W. Monoclonal antibody radioimmunodetection of human-derived colon cancer. Invest Radiol. 1983;18(1):58–62. [PubMed: 6832932]
5.
Primus F.J., Freeman J.W., Goldenberg D.M. Immunological heterogeneity of carcinoembryonic antigen: purification from meconium of an antigen related to carcinoembryonic antigen. Cancer Res. 1983;43(2):679–85. [PubMed: 6401222]
6.
Kenanova V., Olafsen T., Crow D.M., Sundaresan G., Subbarayan M., Carter N.H., Ikle D.N., Yazaki P.J., Chatziioannou A.F., Gambhir S.S., Williams L.E., Shively J.E., Colcher D., Raubitschek A.A., Wu A.M. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. Cancer Res. 2005;65(2):622–31. [PMC free article: PMC4154799] [PubMed: 15695407]
7.
Wu A.M., Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 2008;14(3):191–7. [PubMed: 18536559]
8.
Olafsen T., Wu A.M. Antibody vectors for imaging. Semin Nucl Med. 2010;40(3):167–81. [PMC free article: PMC2853948] [PubMed: 20350626]
9.
Wu A.M. Antibodies and antimatter: the resurgence of immuno-PET. J Nucl Med. 2009;50(1):2–5. [PubMed: 19091888]
10.
Arbabi Ghahroudi M., Desmyter A., Wyns L., Hamers R., Muyldermans S. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. 1997;414(3):521–6. [PubMed: 9323027]
11.
Desmyter A., Decanniere K., Muyldermans S., Wyns L. Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem. 2001;276(28):26285–90. [PubMed: 11342547]
12.
Muyldermans S. Single domain camel antibodies: current status. J Biotechnol. 2001;74(4):277–302. [PubMed: 11526908]
13.
Cortez-Retamozo V., Backmann N., Senter P.D., Wernery U., De Baetselier P., Muyldermans S., Revets H. Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 2004;64(8):2853–7. [PubMed: 15087403]
14.
Vaneycken I., Govaert J., Vincke C., Caveliers V., Lahoutte T., De Baetselier P., Raes G., Bossuyt A., Muyldermans S., Devoogdt N. In vitro analysis and in vivo tumor targeting of a humanized, grafted nanobody in mice using pinhole SPECT/micro-CT. J Nucl Med. 2010;51(7):1099–106. [PubMed: 20554727]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this page (76K)
  • MICAD Summary (CSV file)

Search MICAD

Limit my Search:


Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...